Scientific Advisory Board
The PEARRL Scientific Advisory Board (PSAB) consists of well recognised external experts from academic, industry and regulatory with the aim of bringing independent advice and additional viewpoints to the PEARRL research and training programme. Their tasks include; advising the supervisory board on scientific and training related matters, reviewing annual ESR reports delivered by the researcher committees and participating in open discussions with PEARRL researchers.
Director, DCP I (Division of Clinical Pharmacology I), OCP (Office of Clinical Pharmacology), in CDER (Center for Drug Evaluation and Research), FDA, USA
Expertise in: therapeutic equivalence of complex modified release products, disease progression modeling in Parkinson’s disease, efficacy extrapolation in pediatrics for epilepsy drugs, and possible extension of BCS based biowaivers